Toxins TcdA and TcdB are the main virulence factors of Clostridioides difficile, a leading cause of hospital-acquired diarrhea. Despite their importance, there is a significant knowledge gap of druggable targets for inhibiting toxin production. To address this, we screened non-antibiotic phytochemic …

HA-CDI is associated with a higher risk of anastomotic leak after oncological colorectal surgery, while asymptomatic CDC do not have higher morbidity and may be operated electively, under standard CD treatment.

Global Clostridium Diagnostics Market is valued at approximately USD 838.05 million in 2022 and is anticipated to grow with a healthy growth rate of more than 7.10% over the forecast period 2023-2030.

C. diff survivor and Peggy Lillis Foundation Board Member Maryann Webb discusses how her experience with the infection encouraged her to advocate for patients who are struggling to advocate for themselves.

The Business Research Company recently released a comprehensive report on the Global Difficile Associated Diarrhea Treatment Market Size and Trends Analysis with Forecast 2024 2033 This latest market research report offers a wealth of valuable insights and data including global ...

Acurx reports ibezapolstat's positive microbiome effects and Anthrax activity

• One hundred seven patients with cystic fibrosis (CF) and 54 other patients with risk factors for Clostridium difficile–associated disease were entered into a bacteriologic study to compare the rate of recovery of C difficile and cytotoxin in feces with occurrence of diarrhea and to investigate...

Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea. The bacterium's intrinsic drug resistance limits current treatment options to fidaxomicin and vancomycin for initial episodes, with anti-toxin B monoclonal antibod …

Study halted due to ineffective results, but the findings still provide valuable insights for future research and improve treatment strategies for those affected by CDI.

Hello, it's Ashleigh coming to you from New York this week where the city is flooded with world leaders for the UN General Assembly. On Thursday the buzz of attention shifted to the “silent pandemic” of antimicrobial resistance. But first...

Fecal microbiota-based therapies are becoming more prevalent in the management of Clostridioides difficile infection.

More commonly known as C. diff, Clostridioides difficile is a microbe known to cause diarrhoea, colitis and other bowel complications

Publisher Correction: Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022

The diagnosis of Clostridioides difficile infection (CDI) in the pediatric population is complicated by the high prevalence of asymptomatic colonization, particularly in infants. Many laboratory diagnostic methods are available, but there continues to be controversy over the optimal laborator …

A preventive strategy based on systematic LTBI screening and moxifloxacin treatment before LT in positive cases appears safe and effective in preventing the development of tuberculosis in LT recipients. However, our findings are limited by a small sample size; thus, larger studies are required to va …

Which trials do we need? Fidaxomicin plus either intravenous metronidazole or tigecycline versus vancomycin plus either intravenous metronidazole or tigecycline for fulminant Clostridioides difficile infection

The far UV-C light technology could potentially be useful for automated decontamination of air and surfaces in bathrooms in healthcare and community settings.

Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The

Our findings are consistent with the previous studies that suggested the incubation period for CDI is typically less than 1 week and is less than 2 weeks in most cases.

The fact that our caFMT compared similarly to the imported caFMT was viewed as a success in terms of quality assurance. Our caFMT had a slightly lower success rates compared to data from other studies, but could be affected by several other factors than our FMT-production methods. A lower success ra …

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

Mainly performed within a rapid diagnostic tests company, a lateral flow (LF) system using gold nanoparticles (AuNPs) as transducers is presented able to detect three bacteria of interest, of relevance for antimicrobial resistance (AMR): Clostridioides difficile, methicillin-resistant Staphylococcus …

Our study suggests that the differing gut microbiota profiles in pediatric CDI patients may contribute to disease recurrence by modulating SCFA concentrations and bile acid profiles. The gut microbiota and metabolite signatures may be used to predict disease recurrence in children with CDI.

Clostridioides difficile infection (CDI) is a health crisis comprising a majority of healthcare-associated infections and is now being seen in the community. Persistent dysbiosis despite treatment with standard-of-care antibiotics increases risk of recurrent infections. Fecal microbiota trans …

Maryann Webb’s harrowing, personal experience with C diff, along with her professional work with federal agencies has prepared her for a life in advocacy with the Peggy Lillis Foundation. She wants to see the fecal microbiota transplant become more accessible and is working with Congress to make the infection a notifiable infectious disease.

Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea. The bacterium's intrinsic drug resistance limits current treatment options to fidaxomicin and vancomycin for initial episodes, with anti-toxin B monoclonal antibod …

In the period spanning 2017-2021, a mere 12 new antibiotics entered the market, with only one capable of targeting all the pathogens deemed critical by the WHO.

Cross-regional strains may spread more effectively in the community, highlighting the need for ongoing molecular surveillance to monitor their prevalence and detect potential changes.

Clostridioides difficile infection (CDI) is a major cause of healthcare- and antibiotic-associated diarrhea. While fecal microbiota transplantation (FMT) shows promise for recurrent CDI, its mechanisms and long-term safety are not fully understood. Live biotherapeutic products (LBPs) using pre-defin …

Acurx readies ibezapolstat for Phase 3 CDI trials